What is the appropriate meropenem dosing regimen for an adult with acute kidney injury?

Meropenem Dosing in Acute Kidney Injury

For adults with AKI, meropenem dosing must be reduced based on creatinine clearance, with the recommended dose being 500 mg every 12 hours for CrCl 26-50 mL/min, 250 mg every 12 hours for CrCl 10-25 mL/min, and 250 mg every 24 hours for CrCl <10 mL/min for skin/soft tissue infections (or double these doses for intra-abdominal infections). 1

Standard Dosing Adjustments by Renal Function

The FDA-approved meropenem dosing for adults with renal impairment follows a clear algorithm based on creatinine clearance 1:

• CrCl >50 mL/min: Full dose (500 mg q8h for complicated skin infections; 1 g q8h for intra-abdominal infections) 1
• CrCl 26-50 mL/min: Recommended dose every 12 hours instead of every 8 hours 1
• CrCl 10-25 mL/min: Half the recommended dose every 12 hours 1
• CrCl <10 mL/min: Half the recommended dose every 24 hours 1

When only serum creatinine is available, use the Cockcroft-Gault equation to estimate creatinine clearance, adjusting for sex (multiply by 0.85 for females) 1.

Critical Considerations for Severe Infections

For infections caused by Pseudomonas aeruginosa, even patients with preserved renal function require 1 g every 8 hours rather than 500 mg. 1 This higher dose requirement persists in AKI but must be adjusted according to the renal dosing table above.

The pharmacodynamic target for beta-lactams like meropenem is time-dependent, with optimal efficacy requiring the free drug concentration to remain above the MIC for at least 40-100% of the dosing interval 2, 3. In critically ill patients with AKI, achieving these targets becomes more challenging due to altered pharmacokinetics 4, 5.

Special Populations and Modalities

Patients on Continuous Renal Replacement Therapy (CRRT)

For patients receiving CRRT, the dosing strategy differs significantly from intermittent hemodialysis 6, 5, 7:

• Standard CRRT (20-25 mL/kg/h effluent rate): 750 mg every 8 hours or 1 g every 8-12 hours achieves adequate targets for pathogens with MIC ≤2 mg/L 8, 5, 9
• High-intensity CRRT (35 mL/kg/h): Similar dosing of 750 mg every 8 hours remains appropriate 8, 9
• Residual diuresis matters: Patients with preserved urine output (>500 mL/24h) may require higher doses or prolonged infusions compared to oliguric patients 5

Extended infusions (3 hours) or continuous infusions may be superior to bolus dosing in CRRT patients to maintain adequate drug levels throughout the dosing interval 3, 6, 7.

Inadequate Data for Hemodialysis

The FDA label explicitly states there is inadequate information regarding meropenem use in patients on intermittent hemodialysis or peritoneal dialysis. 1 This represents a significant knowledge gap requiring clinical judgment and potentially therapeutic drug monitoring.

Pediatric Dosing in AKI

For pediatric patients ≥3 months with normal renal function, doses range from 10-40 mg/kg every 8 hours depending on infection type (maximum 2 g per dose) 1. However, there is no published experience with dose adjustments in pediatric patients with renal impairment. 1 Extrapolation from adult data using eGFR normalized for maturation may be reasonable 10.

Toxicity Monitoring

While achieving adequate drug exposure is critical, meropenem trough concentrations >45 mg/L are associated with increased risk of neurotoxicity, particularly seizures. 2, 3, 7 This risk is heightened in patients with renal dysfunction where drug accumulation occurs 2. The relative pro-convulsive activity of meropenem is moderate (16% compared to penicillin G at 100%) but still clinically relevant 2.

Practical Algorithm

1. Calculate creatinine clearance using Cockcroft-Gault equation 1
2. Identify infection type and pathogen (if known) to determine base dose requirement 1
3. Apply renal dosing adjustment per FDA table 1
4. Consider extended infusion (3 hours) in critically ill patients or those with difficult-to-treat pathogens 2, 3, 7
5. For CRRT patients: Use 750 mg-1 g every 8 hours regardless of effluent rate 8, 5, 9
6. Monitor for neurotoxicity especially if multiple doses have been given or if trough levels are available 2, 3

Common Pitfalls

• Failing to adjust for body weight in Cockcroft-Gault calculation leads to inaccurate CrCl estimates 1
• Using standard doses in patients with CrCl 26-50 mL/min risks toxicity accumulation 1
• Assuming CRRT removes all drug and using full doses can lead to excessive levels 6, 5
• Not accounting for residual renal function in CRRT patients may result in underdosing 5
• Extrapolating adult data directly to pediatric AKI patients without considering developmental pharmacokinetics 10